• Company
• ‘1+3 will also impact Korea’s patent linkage system'
• by Kim, Jin-Gu Nov 20, 2023 05:50am

• Opinion
• [Reporter’s View] 1 yr after Zerbaxa's release
• by Eo, Yun-Ho Nov 20, 2023 05:50am

• Policy
• Results of the 2nd price ceiling reevals to be released soon
• by Lee, Tak-Sun Nov 20, 2023 05:50am

• Company
• 160 billion won Daewoong·Takeda Luphere·Leuplin
• by Nho, Byung Chul Nov 17, 2023 06:00am

• Company
• New drug Camzyos can be prescribed at hospitals
• by Eo, Yun-Ho Nov 17, 2023 06:00am

• Company
• GC Biopharma’s Hunterase approved after 11yrs
• by Chon, Seung-Hyun Nov 17, 2023 05:59am

• Policy
• Takeda Obizur accepts results of the drug rating
• by Lee, Tak-Sun Nov 17, 2023 05:59am

• Company
• Will Keytruda’s receive reimb for TNBC in KOR?
• by Eo, Yun-Ho Nov 17, 2023 05:59am

• Company
• Large companies more actively engage in patent challenges
• by Kim, Jin-Gu Nov 17, 2023 05:59am

• Opinion
• [Reporter’s View]Encouraging healthy competition in NSCLC
• by Son, Hyung-Min Nov 16, 2023 05:46am